812.21 HMGLPTHLATER

CH

Art. 10 Loi fédérale du 15 décembre 2000 sur les médicaments et les dispositifs médicaux (LPTh) - Conditions liées à l’autorisation de mise sur le marché

LPTh; Chapitre 2 Médicaments

Ouvrir la source officielle Texte complet (141 Articles) Version Markdown lisible par machine (.md)

Art. 10 LPTh · Conditions liées à l’autorisation de mise sur le marché

Quiconque sollicite l’autorisation de mise sur le marché doit: a. apporter la preuve que le médicament avec mention de l’indication ou le procédé concernés sont de qualité, sûrs et efficaces; abis. pouvoir en tout temps, à l’aide d’une documentation et pour tout médicament de la médecine complémentaire sans mention de l’indication: 1. apporter la preuve qu’il est de qualité, et 2. établir de manière plausible qu’il ne présente aucun risque pour la sécurité des consommateurs; b. être titulaire d’une autorisation de fabriquer, d’importer ou de faire le commerce de gros délivrée par l’autorité compétente; c. avoir son domicile ou son siège social en Suisse, ou y avoir fondé une filiale.

L’institut vérifie que les conditions liées à l’autorisation de mise sur le marché sont remplies. À cet effet, il peut effectuer des inspections axées sur le produit.

← Art. 9b LPTh Loi fédérale du 15 décembre 2000 sur les médicaments et les dispositifs médicaux (LPTh) - But Art. 11 LPTh →

Décisions judiciaires appliquant cette disposition (25)

C-1664/2019 (Art. 10 al. 1 let. a LPTh)

Pharmaceutical Company Denied Market Authorization for Acne Gel

Requirement for the applicant to prove the quality, safety, and efficacy of the drug.

C-2645/2014 (Art. 10 Abs. 2 HMG)

Responsible Person's Unauthorized Drug Distribution Leads to Permit Suspension

This provision is cited as the basis for determining the trustworthiness of the responsible technical personnel, which is a prerequisite for maintaining the operating license.

A-3621/2014 (Art. 10 al. 1 let. a LPTh)

Pharmaceutical Product Approval Document Access Dispute

Cited in relation to the requirements for obtaining marketing authorization.

C-568/2013 (Art. 10 Abs. 1 Bst. a HMG)

Fixed-Combination Bronchial Lozenge Application Rejection Upheld

Requires that a medicinal product must be of high quality, safe, and effective to be authorized.

C-2532/2013 (Art. 10 Abs. 1 Bst. a HMG)

Biowaiver Denial Upheld Due to Insufficient Data and Quality Control Deficiencies

This provision states that a drug must be proven to be of high quality, safe, and effective for approval, a key criterion in the decision.

C-4776/2010 (Art. 10 Abs. 1 Bst. a HMG)

E.________-_______ Generic Drug Marketing Authorization Rejection Upheld

Cited as a fundamental requirement for drug approval, stipulating that the product must be of high quality, safe, and effective.

C-4776/2010 (Art. 10 HMG)

E.________-_______ Generic Drug Marketing Authorization Rejection Upheld

Cited as the basis for general admission requirements for medicinal products, setting the framework for the specific rules applied.

C-4687/2010 (art. 10 cpv. 1 lett. a LATer)

Anesthetic Homologation Denied Due to Insufficient Safety Evidence

Cited in the context of the applicant's obligation to demonstrate that the preparation meets legal requirements, particularly regarding safety.

C-7594/2008 (Art. 10 cpv. 1 lett. a e b LATer)

Marketing Authorization Appeal for Carbon Dioxide Local Anesthetic

Cited to outline the requirements for a marketing authorization application, including quality, safety, and efficacy.

C-2790/2010 (Art. 10 Abs. 1 Bst. a HMG)

Pharmaceutical Company v. Regulatory Authority: Marketing Authorization Suspension Upheld

Basis for requiring the applicant to prove the quality, safety, and efficacy of the medicinal product.

C-1922/2009 (art. 10 al. 1 let. a LPTh)

Pharmaceutical Company Denied Market Authorization Due to Insufficient Quality and Safety Data

Cited as a legal requirement for the applicant to prove the quality, safety, and efficacy of the medicinal product.

36.2011.49 · ti (Art. 10 cpv. 1 lett. a LATer)

Health Insurance Reimbursement for Off-Label Psoriatic Arthritis Medication

Cited concerning the applicant's duty to attest to the quality, safety, and efficacy of the medicine.

C-6050/2008 (Art. 10 HMG)

Seizure of Unapproved Medication for Personal Use Upheld

Stipulates that medicines are approved in Switzerland, not just active substances.

C-2261/2006 (Art. 10 cpv. 1 lett. a LATer)

Swissmedic Denies Local Anesthetic Registration Due to Safety Concerns

The court used this article to establish that the applicant must demonstrate the quality, safety, and efficacy of the medication to obtain marketing authorization.

C-2251/2006 (Art. 10 Abs. 1 Bst. a HMG)

Patented Formulation Blocks Parallel Import of Medicine

Requires applicants to demonstrate that their medicinal product is of high quality, safe, and effective.